Business
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nNR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and ingredient quality\n\n\n LOS ANGELES--(BUSINESS WIRE)--\nNiagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes a global benchmark for what high-quality NRCl should look like in dietary supplements, limiting adulterants and contaminants.\n\n\nRob Fried, Chief Executive Officer of Niagen Bioscience, said, “This monograph is a meaningful development for the broader NAD+ supplement industry because NR now has a published pharmacopeial standard, while NMN and NAD+ do not. It underscores the importance of doing the long-term scientific and technical work required to help define a quality standard.”\n\n\nUSP is an independent, nonprofit organization that develops official quality standards for medicines, food ingredients, and dietary supplements. The U.S. Food & Drug Administration (FDA) and international regulatory bodies use USP standards as a primary reference point for evaluating the quality of a drug or ingredient, including purity, potency, identity, and testing methods.\n\n\nAron Erickson, Vice President, Research and Development at Niagen Bioscience, commented, \"The monograph for NRCl is based on the scientific data, analytical methods, and specifications that we established for Niagen.\"\n\n\nNiagen Bioscience collaborated with USP for six years as the sponsor of the monograph effort, contributing analytical methods, specifications, and testing approaches that helped establish the NRCl standard. The published monograph includes concrete quality requirements for NRCl, including identity testing, assay specifications, impurity limits, contaminant and microbial requirements, and packaging and storage requirements.\n\n\nThe monograph is available in USP’s compendia with a license and is expected to be codified and enforced in October 2026.\n\n\nFor additional information on...